xCystence Bio has received a top-up grant from CUREator, the national biotechnology incubator run by Brandon BioCatalyst, bringing CUREator's total funding for the company to A$750,000. Top-up rounds are awarded to projects that have progressed since their initial seed funding.
The funding moves xCystence's programme towards preclinical proof of concept, as a step towards clinical development of new treatments for polycystic kidney disease.
xCystence Bio was founded by Professor Ian Smyth and Dr Denny Cottle of the Monash Biomedicine Discovery Institute, and Professor Paul Stupple and Dr Yichao Zhao of the Monash Institute of Pharmaceutical Sciences.
Read the full release from the Monash Biomedicine Discovery Institute